Please assess the completion status of the following clinical trial:

Trial Title: 2nd Study to Assess ISV-305 Compared to Vehicle for Treatment of Inflammation and Pain Associated With Cataract Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Are at least 17 years of age~* Are scheduled for uncomplicated unilateral cataract surgery~* Signature of the subject or parent(s) or legally authorized representative on the Informed Consent Form, and when appropriate the minor's assent in accordance with local regulations~* Are willing and able to follow all instructions and attend all study visits~* Are willing to avoid disallowed medication for the duration of the study~* If female is of childbearing potential, agree to and submit a urine sample for pregnancy testing (prior to enrollment and at the end of the study) and use effective contraception for the duration of the study~* Male subjects whose female partners are not post-menopausal must agree to one of the following: 1) completely abstain from sexual intercourse, 2) use a barrier method (condoms) with spermicide during sexual intercourse for the duration of the study, 3) provide documentation for having had a vasectomy (with documented infertility)~* Additional inclusion criteria also apply~Exclusion Criteria:~* Have known sensitivity or poor tolerance to any component of the study drugs~* Have any sign of iritis or scleritis in the study eye~* Have an acute ocular infection (bacterial, viral or fungal) or active ocular inflammation in the study eye~* Have any active or chronic/recurrent ocular or systemic disease that is uncontrolled and likely to affect wound healing (e.g., diabetes mellitus, systemic connective tissue disease, severe atopic disease)~* Have known blood dyscrasia or bone marrow suppression~* Have any active corneal pathology in the study eye~* Have had radial keratotomy, corneal transplant, or LASIK in the study eye within the last 2 years~* Be currently pregnant, nursing, or planning a pregnancy; or have a positive urine pregnancy test~* Have prior (within 30 days of beginning study treatment) or anticipated concurrent use of an investigational drug or device~* Have a condition or a situation which, in the investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation~* Use of any medication the investigator feels may interfere with the study parameters~* Additional exclusion criteria also apply

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ISV-305 (Type: EXPERIMENTAL): 0.1% dexamethasone in DuraSite® 2
- Vehicle (Type: PLACEBO_COMPARATOR): DuraSite® 2 vehicle

Based on this trial design, predict the completion outcome and termination type (if applicable).